Literature DB >> 19965668

PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.

Cong Peng1, Yaoyu Chen, Zhongfa Yang, Haojian Zhang, Lori Osterby, Alan G Rosmarin, Shaoguang Li.   

Abstract

The tumor suppressor gene phosphatase and tensin homolog (PTEN) is inactivated in many human cancers. However, it is unknown whether PTEN functions as a tumor suppressor in human Philadelphia chromosome-positive leukemia that includes chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL) and is induced by the BCR-ABL oncogene. By using our mouse model of BCR-ABL-induced leukemias, we show that Pten is down-regulated by BCR-ABL in leukemia stem cells in CML and that PTEN deletion causes acceleration of CML development. In addition, overexpression of PTEN delays the development of CML and B-ALL and prolongs survival of leukemia mice. PTEN suppresses leukemia stem cells and induces cell-cycle arrest of leukemia cells. Moreover, PTEN suppresses B-ALL development through regulating its downstream gene Akt1. These results demonstrate a critical role of PTEN in BCR-ABL-induced leukemias and suggest a potential strategy for the treatment of Philadelphia chromosome-positive leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965668      PMCID: PMC2810991          DOI: 10.1182/blood-2009-06-228130

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention.

Authors:  Jiwang Zhang; Justin C Grindley; Tong Yin; Sachintha Jayasinghe; Xi C He; Jason T Ross; Jeffrey S Haug; Dawn Rupp; Kimberly S Porter-Westpfahl; Leanne M Wiedemann; Hong Wu; Linheng Li
Journal:  Nature       Date:  2006-04-23       Impact factor: 49.962

2.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN.

Authors:  Lenin Mahimainathan; Falguni Das; Balachandar Venkatesan; Goutam Ghosh Choudhury
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

4.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Authors:  Mei-Ling Chen; Pei-Zhang Xu; Xiao-ding Peng; William S Chen; Grace Guzman; Ximing Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Nissim Hay
Journal:  Genes Dev       Date:  2006-06-15       Impact factor: 11.361

5.  Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners.

Authors:  Péter Várnai; Tzvetanka Bondeva; Péter Tamás; Balázs Tóth; László Buday; László Hunyady; Tamas Balla
Journal:  J Cell Sci       Date:  2005-10-15       Impact factor: 5.285

6.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Authors:  Omer H Yilmaz; Riccardo Valdez; Brian K Theisen; Wei Guo; David O Ferguson; Hong Wu; Sean J Morrison
Journal:  Nature       Date:  2006-04-05       Impact factor: 49.962

7.  The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.

Authors:  M M Georgescu; K H Kirsch; T Akagi; T Shishido; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

8.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Authors:  Yiguo Hu; Sarah Swerdlow; Theodore M Duffy; Roberto Weinmann; Francis Y Lee; Shaoguang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

9.  Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.

Authors:  Jian Wang; Weiming Ouyang; Jingxia Li; Lixin Wei; Qian Ma; Zhuo Zhang; Qiangsong Tong; Jie He; Chuanshu Huang
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

10.  The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.

Authors:  I Bruns; A Czibere; J C Fischer; F Roels; R-P Cadeddu; S Buest; D Bruennert; A N Huenerlituerkoglu; N H Stoecklein; R Singh; L F Zerbini; M Jäger; G Kobbe; N Gattermann; R Kronenwett; B Brors; R Haas
Journal:  Leukemia       Date:  2009-01-22       Impact factor: 11.528

View more
  57 in total

1.  Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.

Authors:  Shiuan Wey; Biquan Luo; Chun-Chih Tseng; Min Ni; Hui Zhou; Yong Fu; Deepa Bhojwani; William L Carroll; Amy S Lee
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells.

Authors:  Haojian Zhang; Huawei Li; Hualin S Xi; Shaoguang Li
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

Review 3.  The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

Authors:  Bing Z Carter; Duncan H Mak; Jorge Cortes; Michael Andreeff
Journal:  Semin Hematol       Date:  2010-10       Impact factor: 3.851

Review 4.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

5.  Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.

Authors:  Justyna A Janas; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

6.  A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Con Sullivan; Cong Peng; Yi Shan; Yiguo Hu; Dongguang Li; Shaoguang Li
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

Review 7.  Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Authors:  Y Chen; C Peng; C Sullivan; D Li; S Li
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

8.  Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia.

Authors:  Haojian Zhang; Huawei Li; Ngoc Ho; Dongguang Li; Shaoguang Li
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

9.  Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia.

Authors:  Xia Zhang; Riming Liu; Baohua Huang; Xiaolu Zhang; Weijuan Yu; Cuixia Bao; Jie Li; Chengming Sun
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

Review 10.  Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.

Authors:  Haojian Zhang; Shaoguang Li
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.